JP2008504335A5 - - Google Patents

Download PDF

Info

Publication number
JP2008504335A5
JP2008504335A5 JP2007518555A JP2007518555A JP2008504335A5 JP 2008504335 A5 JP2008504335 A5 JP 2008504335A5 JP 2007518555 A JP2007518555 A JP 2007518555A JP 2007518555 A JP2007518555 A JP 2007518555A JP 2008504335 A5 JP2008504335 A5 JP 2008504335A5
Authority
JP
Japan
Prior art keywords
nucleic acid
double
building blocks
molecule
nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007518555A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008504335A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2005/007198 external-priority patent/WO2006002971A2/en
Publication of JP2008504335A publication Critical patent/JP2008504335A/ja
Publication of JP2008504335A5 publication Critical patent/JP2008504335A5/ja
Pending legal-status Critical Current

Links

JP2007518555A 2004-07-02 2005-07-04 Hmgb1に関連する病変の治療のための核酸 Pending JP2008504335A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US58467804P 2004-07-02 2004-07-02
US64658605P 2005-01-26 2005-01-26
PCT/EP2005/007198 WO2006002971A2 (en) 2004-07-02 2005-07-04 Nucleic acids for the treatment of hmgb1-related pathologies

Publications (2)

Publication Number Publication Date
JP2008504335A JP2008504335A (ja) 2008-02-14
JP2008504335A5 true JP2008504335A5 (https=) 2008-08-21

Family

ID=35106975

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007518555A Pending JP2008504335A (ja) 2004-07-02 2005-07-04 Hmgb1に関連する病変の治療のための核酸

Country Status (14)

Country Link
US (1) US20080305073A1 (https=)
EP (1) EP1768677B1 (https=)
JP (1) JP2008504335A (https=)
AT (1) ATE399014T1 (https=)
AU (1) AU2005259381A1 (https=)
BR (1) BRPI0512944A (https=)
CA (1) CA2572519A1 (https=)
DE (1) DE602005007746D1 (https=)
DK (1) DK1768677T3 (https=)
ES (1) ES2306195T3 (https=)
IL (1) IL179828A0 (https=)
PL (1) PL1768677T3 (https=)
PT (1) PT1768677E (https=)
WO (1) WO2006002971A2 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5188804B2 (ja) 2004-08-03 2013-04-24 トランステック ファーマ,インコーポレイティド Rage融合タンパク質及びその使用方法
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
KR20080105066A (ko) * 2006-02-09 2008-12-03 트랜스테크 파르마, 인크. Rage 융합 단백질 및 이의 사용 방법
JP3882090B1 (ja) * 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
CN101589309A (zh) * 2006-11-17 2009-11-25 临床基因网络公司 涉及基因gypc、agpat3、agl、pvrl2、hmgb3、hsdl2和/或ldb2的筛选和治疗方法
US20100056608A1 (en) * 2006-11-17 2010-03-04 Clinical Gene Networks Ab Methods for screening and treatment involving the genes gypc, agpat3, agl, pvrl2, hmgb 3, hsdl2 and/or ldb2
US8927510B2 (en) 2008-05-16 2015-01-06 Children's Medical Center Corporation Compositions and methods for inhibition of retroviruses
WO2009149921A2 (en) * 2008-06-11 2009-12-17 Bionucleon S.R.L. Inhibition of hrp-3 using modified oligonucleotides
DK2329266T3 (en) 2008-09-11 2016-07-18 Pasteur Institut MONITORING AND INHIBITING INFECTION WITH HUMAN IMMUNE DEFECT VIRUS BY MODULATING HMGB1-DEPENDENT TRACTOR OF HIV-1 REPLICATION AND PERSISTENCE
US20120165244A1 (en) * 2008-10-30 2012-06-28 Hua-Lin Wu Methods for binding lewis y antigen
PT2381964E (pt) 2008-12-22 2014-08-29 Creabilis S A Síntese de conjugados poliméricos de compostos de indolocarbazol
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
GB0911569D0 (en) * 2009-07-03 2009-08-12 Ulive Entpr Ltd Method for the detection of organ or tissue injury
JP5467313B2 (ja) * 2009-09-28 2014-04-09 国立大学法人 岡山大学 アテローム動脈硬化抑制剤
US8975019B2 (en) * 2009-10-19 2015-03-10 University Of Massachusetts Deducing exon connectivity by RNA-templated DNA ligation/sequencing
WO2012036215A1 (ja) 2010-09-17 2012-03-22 Taniguchi Tadatsugu Hmgbタンパクによって仲介される免疫応答の活性化の抑制剤及びスクリーニング方法
US20140378531A1 (en) * 2012-02-01 2014-12-25 New York University Inhibition of pattern recognition receptors in pancreatic cancer treatment using tlr inhibitors
JP6624542B2 (ja) * 2015-02-05 2019-12-25 国立大学法人広島大学 ヒトhmgb1結合剤およびヒトhmgb1除去装置
WO2018175340A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Reduced exposure conjugates modulating therapeutic targets
WO2018175315A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates of staurosporine derivatives having reduced exposure
WO2018175301A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugate of montesanib with reduced exposure
WO2018175302A1 (en) 2017-03-20 2018-09-27 Sienna Biopharmaceuticals, Inc. Polymer conjugates targeting c-src with reduced exposure
EP3621657A1 (en) 2017-05-10 2020-03-18 Sienna Biopharmaceuticals, Inc. Uses of polymer conjugates of indolocarbazole compounds with reduced exposure
CN111304202B (zh) * 2020-02-26 2023-03-28 西安交通大学 一种用于识别且增强hmgb1生物学活性的核酸适配子及其应用
CN114957440A (zh) * 2022-05-26 2022-08-30 江苏大学 一种重组HMGB1 A Box蛋白及其获取方法与应用
EP4543459A1 (en) * 2022-06-23 2025-04-30 The J. David Gladstone Institutes, A Testamentary Trust Established under The Will of J. David Gladstone Hmgb1 inhibitors for treatment of apoe4-related tauopathies including alzheimer's disease
CN114807150B (zh) * 2022-06-28 2022-10-14 中国科学院基础医学与肿瘤研究所(筹) 靶向和拮抗hmgb1分子的核酸适体
JP2025525583A (ja) 2022-07-19 2025-08-05 ランパート バイオサイエンス インコーポレイテッド 非免疫原性環状非ウイルス性dnaベクター
CN115774004B (zh) * 2022-08-19 2024-07-05 四川大学华西医院 二氧化锆@量子点复合微球在制备检测hmgb1的荧光探针中的用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0672188B1 (en) * 1992-10-14 2003-12-10 NeXstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US7754217B2 (en) * 2001-03-16 2010-07-13 Bio3 Research Srl HMGB1 protein inhibitors and/or antagonists for the treatment of vascular diseases
CA2506328A1 (en) * 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents

Similar Documents

Publication Publication Date Title
JP2008504335A5 (https=)
JP7672163B2 (ja) 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
Ding et al. The HMGB1–TLR4 axis contributes to myocardial ischemia/reperfusion injury via regulation of cardiomyocyte apoptosis
US12577565B2 (en) Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
US8835471B2 (en) Use of angiotensin II agonists
JP6944942B2 (ja) IL4Rα、TRPA1、またはF2RL1を標的とするRNA複合体を用いたアトピー性皮膚炎および喘息の治療
KR20220012284A (ko) 핵산, 약학 조성물, 컨쥬게이트와 이의 제조 방법 및 용도
JP2010533171A5 (https=)
EA022429B1 (ru) АПТАМЕРЫ К β-NGF И ИХ ПРИМЕНЕНИЕ ПРИ ЛЕЧЕНИИ β-NGF-ОПОСРЕДОВАННЫХ ЗАБОЛЕВАНИЙ И РАССТРОЙСТВ
US20120322862A1 (en) Aptamers to 4-1BB and Their Use in Treating Diseases and Disorders
JP2008511300A5 (https=)
RU2017108757A (ru) Лечение связанных с геном-супрессором опухолей заболеваний посредством ингибирования природного транскрипта в антисмысловой ориентации относительно этого гена
JP2008518608A5 (https=)
WO2006002971A2 (en) Nucleic acids for the treatment of hmgb1-related pathologies
JP2015509705A5 (https=)
JP2019513384A (ja) 結合組織成長因子を標的とするrna複合体を用いた特発性肺胞線維症の治療
TW202012624A (zh) 用以調節atxn2 表達之寡核苷酸
JP2021513365A (ja) スクレロスチンに対するアプタマー及びその使用
CN102973554A (zh) 土木香内酯的医药用途
JP2025512835A (ja) 修飾オリゴヌクレオチド
WO2023241591A1 (zh) 调控PCSK9基因活性的siRNA分子
Hattori et al. Nucleic-acid based gene therapy approaches for sepsis
EP4316495A1 (en) Nucleic acid molecule conjugate having prolonged in vivo half-life
CN121001748A (zh) 可编程dna蛋白水解靶嵌合体及其使用方法
TWI335219B (en) Virus therapeutic drug